Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise [Seeking Alpha]
CONATUS PHARMACEUTICALS INC (CNAT)
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.conatuspharma.com/investor-relations
Company Research
Source: Seeking Alpha
Nothing can dim the light that shines from within - Maya Angelou Introduction Conatus Pharmaceuticals ( CNAT ) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative Phase 2b drug candidate currently being evaluated in 3 clinical trials as I alluded to in the summary. On December 6, 2018, Conatus announced in a press release and subsequent conference call that top-line data readout from ENCORE-PH Phase 2b clinical trial in NASH Cirrhosis Portal Hypertension (PH) did not met its primary clinical outcome of significant differences in hepatic venous pressure gradient (HVPG) from baseline to week 24 following emricasan treatment relative to placebo. I purposely do not give a bullish or bearish call in my articles because I want folks to make their investment decisions based on their due diligence and hopefully scientific information/discussion obtain
Show less
Read more
Impact Snapshot
Event Time:
CNAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNAT alerts
High impacting CONATUS PHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics